Oncobiologics (NASDAQ:OTLK) Research Coverage Started at Piper Sandler

Piper Sandler initiated coverage on shares of Oncobiologics (NASDAQ:OTLK – Free Report) in a research report report published on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating on the stock.

OTLK has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncobiologics in a report on Tuesday, November 10th. HC Wainwright lifted their price objective on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research note on Monday, July 27th. BTIG Research reissued a “buy” rating and issued a $4.00 price objective on shares of Oncobiologics in a report on Friday, August 14th. Finally, Wall Street Zen lowered shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.20.

Read Our Latest Report on OTLK

Oncobiologics Price Performance

Oncobiologics stock opened at $0.39 on Thursday. The company’s 50-day moving average is $0.54 and its 200-day moving average is $0.66. The firm has a market capitalization of $94.94 million, a PE ratio of -0.51 and a beta of 0.75. Oncobiologics has a fifty-two week low of $0.16 and a fifty-two week high of $2.54.

Hedge Funds Weigh In On Oncobiologics

An institutional investor recently bought a new stake in Oncobiologics stock. NewEdge Advisors LLC bought a new stake in shares of Oncobiologics, Inc. (NASDAQ:OTLK – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,722 shares of the company’s stock, valued at approximately $27,000. 11.20% of the stock is owned by institutional investors and hedge funds.

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.

See Also

Analyst Recommendations for Oncobiologics (NASDAQ:OTLK)

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.